oral polio vaccine + NA-831

This is a **combination drug** consisting of **oral polio vaccine (OPV)** and **NA-831 (Traneurocin)**. - The **oral polio vaccine** component contains live attenuated poliomyelitis viruses (type 1 and type 3, Sabin strain), typically used to prevent poliomyelitis. - **NA-831** is a small molecule neuroprotective agent also known as Traneurocin, designed to promote neuroprotection and neurogenesis, with potential to improve cognitive function. - This combination is being studied for the **prophylaxis of Covid-19 in adults**. OPV may stimulate innate immunity against SARS-CoV-2, while NA-831 mitigates potential neurological risks (such as vaccine-associated paralytic polio) and addresses the neuroinvasive potential of SARS-CoV-2, as well as potential longer-term neurological sequelae of Covid-19. - NA-831 facilitates neurogenesis, likely through activation of synaptic glutamate AMPA receptors and increasing brain-derived neurotrophic factor (BDNF), supporting cognitive function. - Developed principally by BioMed Industries and its subsidiary NeuroActiva, this combination is undergoing Phase 3 clinical trials for Covid-19 prevention[1][2][3][5][7][8].

Brand names

BioCovax

Other names

OPV-NA831OPV-NA-831OPV-NA 831oral polio vaccine and NA-831